Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

Johnson & Johnson announced the CHMP recommended approval for TECVAYLI (teclistamab) in adults with relapsed or refractory multiple myeloma after at least one prior therapy. The recommendation follows phase 3 results showing improved progression-free and overall survival. The company highlighted the critical need for effective immunotherapies in earlier treatment lines.

Johnson & Johnson (JNJ) plans to divest its orthopedic division, DePuy Synthes, either through a sale to Apollo Global Management for $20B or a spinoff. The move aims to streamline operations, improve profitability, and focus on higher-growth segments. Investors expect the divestiture to accelerate JNJ's transformation toward faster-growing, higher-margin markets.

Apollo Global Management (APO) is nearing a deal for a 16% stake in the New York Yankees, valued at over $12 billion. The investment, structured as credit and equity, includes 8% common equity and 8% convertible preferred stock. Apollo aims to leverage sports' stable cash flows and rising franchise values, though concerns include valuation, lack of control, and media rights uncertainty. APO shares are down 12% this year, and the deal is unlikely to significantly impact earnings.

Johnson & Johnson (JNJ) received EU approval for ICOTYDE, a once-daily oral treatment for moderate-to-severe plaque psoriasis. The approval was based on positive Phase 3 trial data, with about 70% of patients achieving clear or almost clear skin. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. JNJ's stock is currently trading at $272.39, up 0.89%.

Apollo Global Management (APO) is set to acquire a 16% stake in the New York Yankees, valuing the franchise at over $12 billion. The $2.6 billion investment, split between equity and debt, is the largest ownership position outside the Steinbrenner family. Apollo will initially own 8% and receive convertible preferred shares for another 8%. The deal provides the Yankees with financial flexibility and may refinance existing debt. The Steinbrenners retain control with over 60% ownership.

Johnson & Johnson (JNJ) reported positive phase 3 trial results for its bipolar I disorder drug Caplyta, showing significant efficacy. The company offers a 1.93% dividend yield with a 50% payout ratio and a 4.9% 3-year dividend growth rate. JNJ's stock is trading 40.1% above its intrinsic GF Value™ of $193.54. The company has a GF Score™ of 80, reflecting strong financial health and profitability, but weaker valuation and momentum.